Table 5.
Comparison of the 128 Subjects Able to be Followed for 11–20 Years vs the Other 155 Subjects Who Were Enrolled in the Study
| Variable | Groups |
P Value | |
|---|---|---|---|
| Subjects Who Were Followed ≥11 y | Subjects Who Were Followed for <11 y | ||
| No. | 128 | 155 | |
| No. males (%) | 71 (55.5) | 103 (66.5) | .07 |
| Mean age ± SD at study entry (median, range) | 48.58 ± 11.57 (47, 25–76) | 42.59 ± 13.31 (42, 16–75) | .0001 |
| No. with multiple erythema migrans at study entry (%) | 25 (19.5) | 40 (25.8) | .26 |
| No. symptomatic at study entry (%) | 104 (81.3) | 132 (85.2) | .42 |
| Mean no. of symptoms at study entry ± SD (median, range) | 3.41 ± 2.82 (3, 0–10) | 4.33 ± 3.23 (4, 0–11) | .01 |
| No. of patients with ≥6 symptoms at study entry (%) | 33 (25.8) | 48 (31.0) | .36 |
| Mean no. of days of illness until baseline visit ± SD (median, range) | 5.44 ± 6.69 (3, 0–42) | 7.00 ± 8.46 (4, 0–66) | .09 |
Abbreviation: SD, standard deviation.